Abstract
Background: Measurement of bile acid levels has been proven helpful in the detection of hepatic
abnormalities when routine liver function test results are normal or only slightly
elevated. We compared the effectiveness of postprandial serum cholylglycine (CG),
as determined by RIA, with commonly used liver function tests (SGOT, SGPT, alkaline
phosphatase, gamma-glutamyl transpeptidase) in order to detect liver injury in patients
receiving antituberculous agents. Method: We studied 100 patients receiving antituberculous agents. Laboratory tests were
carried out before the initiation of therapy and after 1, 2, 3 and 8 weeks of treatment.
The risk of hepatotoxicity in relation to age (>35 years) and/or the addition of pyrazinamide
to the 6-month isoniazid–rifampin regimen was also assessed. Results: The percentage of patients with hepatic dysfunction detected by abnormal serum CG
levels was significantly greater than that detected with conventional liver function
tests. Neither age over 35 years nor the use of pyrazinamide was associated with a
greater number of abnormalities in liver function tests. Conclusion: Postprandial serum CG by RIA proved to be a sensitive parameter for detecting hepatotoxicity
by antituberculous agents.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation bile acids in man.J Clin Invest. 1983; 71: 1003-1022
- Determinants of serum bile acids in chronic liver disease.Gastroenterology. 1991; 81: 959-964
- Blood cholates in normal subjects and in liver disease.Clin Sci. 1948; 6: 959-964
- Diagnostic effectiveness of serum bile acids in liver disease as evaluated by multivariate statistical methods.Hepatology. 1983; 3: 707-713
- Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary disease. Sensitivity, specificity, and predictive value.Dig Dis Sci. 1983; 28: 129-136
- Tuberculosis in patients with human immunodeficiency virus infection.N Engl J Med. 1991; 324: 1644-1650
- Antituberculous agents.Mayo Clin Proc. 1987; 62: 1129-1136
- Isoniazid, rifampin, and hepatotoxicity.Am Rev Respir Dis. 1986; 133: 963-965
- USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results.Ann Intern Med. 1990; 112: 397-406
- Le toxicité du pyrazinamide dans le traitements antituberculeux.Rev Fr Mal Respir. 1980; 8: 307-320
- Isoniazid hepatotoxicity in children.Am Rev Respir Dis. 1978; 118: 794-796
- Postprandial serum bile acid for the detection of hepatobiliary disease.JAMA. 1973; 225: 292-293
- Results of six `kit' radioimmunoassays for primary bile acids in human serum intercompared.Clin Chem. 1980; 26: 1677-1682
SPSS for windows. Release 6.0. Chicago (IL): SPSS, 1993.
- Changes of plasma bile acid levels and their clinical significance in drug-induced liver injury.Tokai J Exp Clin Med. 1984; 9: 109-117
- Isoniazid-associated hepatitis in 114 patients.Gastroenterology. 1975; 69: 289-302
- Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.Ann Intern Med. 1976; 84: 181-192
- Anti-tuberculous therapy and acute liver failure.Lancet. 1995; 345: 555-556
- Toxic hepatitis with isoniazid and rifampin. A meta-anaylisis.Chest. 1991; 99: 465-471
- Isoniacid-associated hepatitis deaths: a review to available information.Am Rev Respir Dis. 1992; 145: 494-497
- Juandice after rifampicin.Br J Dis Chest. 1970; 64: 90-95
- Hepatite mixte a la rifamycine SV. A propos d'un cas.Therapie. 1986; 41: 421-423
- Rifampicin hepatitis. A clinical and histological study.Lancet. 1974; ii: 421-423
- Treatment of tuberculosis and tuberculosis infection in adults and children.Am J Respir Crit Care Med. 1994; 146: 1622-1633
- Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.Drug Staf. 1996; 15: 394-405
- Hepatotoxicity of antituberculous drugs.Thorax. 1996; 51: 111-113
- Pharmacokinetics of the toxic hydrazinometabolites formed from isoniazid in humans.J Pharmacol Exp Ther. 1985; 235: 566-570
- Risk factors for side-effects of isoniacid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.Eur Respir J. 1996; 9: 2026-2030
- Fulminant hepatitis during treatment with rifampicin, pyrazinamide and ethambutol.Eur J Pediatr. 1987; 146: 290-291
- Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampin and pyrazinamide.Tubercle. 1986; 67: 99-108
- Hepatotoxicidad del tratamiento de la tuberculosis.Med Clin (Barcelona). 1991; 97: 481-485
- Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.Lancet. 1981; i: 171-174
Article info
Publication history
Accepted:
June 8,
1999
Received in revised form:
May 17,
1999
Received:
April 13,
1999
Identification
Copyright
© 1999 Elsevier Science B.V. Published by Elsevier Inc. All rights reserved.
